Status:
COMPLETED
Study Evaluating Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Rheumatoid Arthritis
Inflammation
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to evaluate long-term safety of etanercept in patients with rheumatoid arthritis who successfully have completed open-label safety study 0881A1-301-EU
Eligibility Criteria
Inclusion
- To have completed 0881A1-301-EU study in Spain
- Clinical diagnosis by ACR revised criteria of rheumatoid arthritis.
Exclusion
- Hypersensibility to etanercept or any of its components
- Significant concurrent medical disease
Key Trial Info
Start Date :
July 1 2003
Trial Type :
OBSERVATIONAL
End Date :
October 1 2008
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT00195364
Start Date
July 1 2003
End Date
October 1 2008
Last Update
June 4 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Madrid, Madrid, Spain, 28007